Actoxumab

From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search
Actoxumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetClostridium difficile toxin A
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC6476H10000N1740O2010S45
Molar mass145.9 kg/mol g·mol−1

Actoxumab is a human monoclonal antibody designed for the prevention of recurrence of Clostridium difficile infection.[1]

This drug, along with bezlotoxumab, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School.[2] The project was then licensed to Merck & Co., Inc. for further development and commercialization.[3]

A study compared it with bezlotoxumab (that targets CD toxin-B) and found Actoxumab less effective.[4]

References


 

Actoxumab is part of WikiMD's free ^articles!

^Actoxumab (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available